Phase Ib pilot in 41 patients with chronic spontaneous urticaria unresponsive to antihistamines: TLL-018 10 or 30 mg twice daily was well tolerated (primary endpoint); raised creatine kinase, lipids and glucose were common. Placebo-adjusted UAS7 fell 11.5 and 16.0 at week 4.
RCTn = 41
Yao et al. Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study